North India-based diagnostics and pharmacy chain running NABL/NABH-accredited pathology and radiology centres across Uttar Pradesh and Uttarakhand, plus company-owned retail pharmacy outlets.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 20 | 20 | 20 | 24 | 24 | 24 |
| Reserves | 4 | 7 | 21 | 98 | 114 | 147 |
| Borrowings | 17 | 21 | 36 | 48 | 67 | 54 |
| Other Liabilities | 41 | 49 | 41 | 40 | 68 | 65 |
| Total Liabilities | 82 | 98 | 118 | 211 | 273 | 290 |
| AssetsFixed Assets | 29 | 33 | 48 | 76 | 91 | 101 |
| CWIP | 0 | 0 | 0 | 4 | 5 | 12 |
| Investments | 6 | 7 | 3 | 1 | 47 | 20 |
| Other Assets | 46 | 58 | 66 | 129 | 130 | 156 |
| Total Assets | 82 | 98 | 118 | 211 | 273 | 290 |
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ActivitiesCash from Operating | 6 | 4 | 1 | -29 | 16 |
| Cash from Investing | -11 | -6 | -15 | -36 | -40 |
| Cash from Financing | 3 | 2 | 16 | 67 | 21 |
| SummaryCapital Expenditure | — | — | — | — | — |
| Free Cash Flow | -1 | -1 | -18 | -68 | -26 |
| FCF Margin | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (19.4×) and current (20.4×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 10% growth and a 19× exit, ₹211 only delivers your return if you pay ₹136. The price is currently baking in 19% growth.
EPS grows 10%/yr for 5 years, then fades to 6% over 2, exits at 19×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 10.0% | 11.37 |
| FY28 | 10.0% | 12.51 |
| FY29 | 10.0% | 13.76 |
| FY30 | 10.0% | 15.14 |
| FY31 | 10.0% | 16.65 |
| FY32 | 8.0% ·fade | 17.98 |
| FY33 | 6.0% ·fade | 19.06 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.